王大伟

男， 中国人民解放军总医院， 副教授/副研究员/高级工程师或同等级别

学习/工作经历

放射性药物博士，临床医学博士后
中国人民解放军总医院 高级工程师 科研主任
北京医学会核医学分会放射性药物学组委员
中国医药生物技术协会医工结合分会第一届委员会委员

研究领域和兴趣

放射性药物，心血管方向诊断和治疗，人工智能在医疗设备的应用，医用微型核电池

主要业绩

1.主持：解放军总医院中心创新培育基金：基于α7烟碱型乙酰胆碱受体为靶点的新型正电子分子显像剂的实验研究----用于早期识别动脉粥样硬化易损斑块.2021.01-2022.12。
2.主持：中国医学科学院阜外医院外拨横向项目（新型心脏交感神经显像药物的实验研究，2022.01-2023.12）。
3.主要参与者：《重大新药创制》国家重大科技专项，用于重大疾病诊治的创新 放射性药物研制2014-01至2017-12。
4.主要参与者：国家科技支持计划项目课题，α7脑受体等五种放射性药物研究，2014-01至2016-12。
5.主要参与者：首都临床特色诊疗技术研究及转化应用，经皮介入手术导航系统可行性临床研究，2022-11至2025-11。
6.主要参与者：XX医学工程核心技术研究课题，XX训练致软组织伤的智能电刺激疗效评估与康复系统研究，2022-09至2024-3。
7.第7届全国同位素制备及应用研讨会优秀壁报奖（3/120）。

代表成果

1.Yong Yao, Tian-Jing, Wei, Dawei Wang*, The feasibility of 18F-FDG gated positron emission tomography (PET) for left ventricular dyssynchrony assessment in comparison with 99mTc-MIBI gated single-photon emission computed tomography (SPECT) among patients with prior myocardial infarction, Quant Imaging Med Surg. 2022,12, 2454–2463.
2.Tao Yang†, Dawei Wang†, Xiangyi Chen, Yingkui Liang, Feng Guo, Chunxiao Wu, Liujun Jia, Zhihui Hou, Wenliang Li*, Zuoxiang He* and Xin Wang*.18F-ASEM Imaging for Evaluating Atherosclerotic Plaques Linked to α7-Nicotinic Acetylcholine Receptor.Front. Bioeng. Biotechnol.Volume9. Article684221,01 July 2021.（co-first authors)
3.Dawei Wang; Jizheng Wu; Chen Si*; Emergence of charge density wave and Ising superconductivity in centrosymmetric monolayer 1T-HfTe2, Nano. Research, 1-7 (2023).
4.Dawei Wang; Yong Yao; Shuxia Wang; Huabei Zhang*; Zuoxiang He*; The availability of the α7-nicotinic acetylcholine receptor in early identification of vulnerable atherosclerotic plaques: a study using a novel 18F-Label Radioligand PET, Front. Bioeng. Biotechnol.2021.VOl.9.
5.Yong Yao MD, Da-Wei Wang PhD, Wei Fang MD, Yue-Qin Tian MD, Rui Shen MD, Xiao-Xin Sun MD, Feng Guo BS, Ke-Wei Chu BS, Chen Cui MD, Shi-Hua Zhao MD* and Zuo-Xiang He MD*. Evaluation of left ventricular volumes and ejection fraction by 99mTc-MIBI gated SPECT and 18F-FDG gated PET in patients with prior myocardial infarction. Journal of Nuclear Cardiology. DOI：10.1007/s12350-019-01709-9.
6.Yu Fang, Dawei Wang, Xingyu Xu, Gila Dava, Jianping Liu, Xiang Li, Qianqian Xue, Huan Wang, Jiangshan Zhang and Huabei Zhang*. Preparation, in vitro and in vivo evaluation, and molecular dynamics (MD) simulation studies of novel F-18 labeled tumor imaging agents targeting focal adhesion kinase (FAK)†. RSC Adv,2018,8, 10333-10345.
7.Yu Fang, Dawei Wang, Xingyu Xu, Jianping Liu, AiqinWu, Xiang Li, Qianqian Xue, Huan Wang, Hang Wang, Huabei Zhang*. Synthesis, biological evaluation, and molecular dynamics (MD) simulation studies of three novel F-18 labeled and focal adhesion kinase (FAK) targeted 5-bromo pyrimidines as radiotracers for tumor.European journal of medicinal chemistry, 2017-02-15, Vol.127, p.493-508.
8.Dawei Wang ,Xiangyi Chen ,Tao Yang ,Feng Guo ,Chunxiao Wu ,Ying-Kui Liang*.The availability of the fibroblast activation protein receptor in early identification of vulnerable atherosclerotic plaques: a preclinical study using a 68Ga-FAPI PET.SNMMI 2021 Annual Meeting, June 12-15, 2021.
9.Xiangyi Chen ,Tao Yang ,Feng Guo ,Chunxiao Wu ,Ying-Kui Liang* and Dawei Wang*.A study of 68Ga-FAPI in the imaging of atherosclerosis in New Zealand rabbits.SNMMI 2021 Annual Meeting, June 12-15, 2021.
10. Boyuan Xing, Xiangyi Chen, Yalin Wang, Shuang Li, Ying-Kui Liang*, Dawei Wang*，Evaluating Breast Ultrasound S-Detect Image Analysis for Small Focal Breast Lesions. Frontiers in Oncology.fonc.2022.1030624.

*以上信息由高级会员个人更新和维护。